Our results suggest that expression of ERCC-1 was significantly different in primary tumors and metastatic sites of NSCLC patients with adenocarcinoma and that the serum level of CEA was significantly higher in NSCLC patients with adenocarcinoma. Here, ERCC1 is linked to adenocarcinoma.